GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acarix AB (OSTO:ACARIX) » Definitions » COGS-to-Revenue

Acarix AB (OSTO:ACARIX) COGS-to-Revenue : 0.09 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Acarix AB COGS-to-Revenue?

Acarix AB's Cost of Goods Sold for the three months ended in Mar. 2024 was kr0.14 Mil. Its Revenue for the three months ended in Mar. 2024 was kr1.55 Mil.

Acarix AB's COGS to Revenue for the three months ended in Mar. 2024 was 0.09.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Acarix AB's Gross Margin % for the three months ended in Mar. 2024 was 91.04%.


Acarix AB COGS-to-Revenue Historical Data

The historical data trend for Acarix AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acarix AB COGS-to-Revenue Chart

Acarix AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.27 0.25 0.21 0.15

Acarix AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.16 0.18 0.12 0.09

Acarix AB COGS-to-Revenue Calculation

Acarix AB's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.943 / 6.241
=0.15

Acarix AB's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.139 / 1.552
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acarix AB  (OSTO:ACARIX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Acarix AB's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.139 / 1.552
=91.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Acarix AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Acarix AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Acarix AB (OSTO:ACARIX) Business Description

Traded in Other Exchanges
Address
World Trade Center Malmo, Jungmansgatan 12, Malmo, SWE, 211 19
Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96% certainty.

Acarix AB (OSTO:ACARIX) Headlines

No Headlines